YL-17424, oral KRASmulti inhibitor
YL-17424, KRASmulti, is an inhibitor having high potency and selectivity against the most frequent KRASmutant tumors (KRASG12D, KRASG12V, KRASG12C and KRASamplified), with lower activity against wildtype KRAS, NRAS and HRAS. This differentiated activity as oral drug will be directed towards the patient population having selected KRASmutant cancers. YL-17424 is currently in the IND-enabling stage, expecting to enter the clinic in 2025.